Today: 23 January 2026
Subscribe
Browse Category

LSE:VOD.L News 14 January 2026 - 20 January 2026

Vodafone share price edges up after fresh buyback disclosure — here’s what traders watch next

Vodafone share price edges up after fresh buyback disclosure — here’s what traders watch next

London, Jan 20, 2026, 09:06 GMT — Regular session Shares of Vodafone Group Public Limited Company (VOD.L) edged up slightly in early London trading Tuesday after the telecom giant announced a fresh batch of share buybacks. By 0906 GMT, the stock had crept up around 0.1% to 102.05 pence. (TradingView) Buybacks rarely grab headlines, but their steady flow now features…
20 January 2026
····
Vodafone share price holds near £1 after buyback update as Feb. 5 trading statement looms

Vodafone share price holds near £1 after buyback update as Feb. 5 trading statement looms

London, Jan 18, 2026, 09:06 GMT — Markets have closed. Shares of Vodafone Group (VOD.L) closed Friday almost flat, following the company’s announcement of another share buyback. The stock remained near the £1 mark as the new week began. It matters now since fresh company news is scarce, and the next significant update on operational momentum won’t arrive for weeks.…
18 January 2026
····
Vodafone share price nudges lower as buyback rolls on; UBS keeps Sell call on VOD.L

Vodafone share price nudges lower as buyback rolls on; UBS keeps Sell call on VOD.L

London, Jan 14, 2026, 09:32 GMT — Regular session Vodafone Group shares (VOD.L) slipped on Wednesday following the announcement of yet another buyback program. By 0932 GMT, the stock had fallen roughly 0.4% to 98.3 pence, after dropping 2.6% the previous day. (Investing) This matters because Vodafone’s buyback now stands as the primary near-term support for the stock, with investors…
14 January 2026
····

Stock Market Today

  • 10x Genomics (TXG) Stock Valuation Examined After Sharp Price Gains
    January 23, 2026, 12:15 PM EST. 10x Genomics (TXG) has seen a recent share price surge with a 40.55% increase over one month and a 68.41% rise in 90 days, driven by investor interest in genomics tools. Despite this momentum, the stock trades at $23.19, above the average analyst price target of $18.23 and a narrative-based fair value of $17.36, suggesting possible overvaluation. The company's acquisition of Scale Biosciences enhances its single-cell analysis capabilities, potentially boosting future revenue and margins. Risks remain, including reduced research funding and pricing pressures that may affect growth expectations. Investors are urged to weigh these factors as 10x Genomics' long-term total shareholder returns have been weaker. The stock's elevated price demands careful consideration of the underlying growth story and market assumptions.
Go toTop